

# PUBLIC SUBMISSION

<b>As of:</b> 1/30/19 12:13 PM <b>Received:</b> January 29, 2019 <b>Status:</b> Pending_Post <b>Tracking No.</b> 1k3-97yj-jnfw <b>Comments Due:</b> January 29, 2019 <b>Submission Type:</b> Web
---

**Docket:** NRC-2018-0230

Training and Experience Requirements for Different Categories of Radiopharmaceuticals

**Comment On:** NRC-2018-0230-0001

Training and Experience Requirements for Different Categories of Radiopharmaceuticals

**Document:** NRC-2018-0230-DRAFT-0118

Comment on FR Doc # 2018-23521

## Submitter Information

**Name:** Akintunde Orunmuyi

**Address:**

Nuclear Medicine Department UCH Ibadan  
 Queen Elisabeth Road  
 Ibadan, OYO, Nigeria, 200222

**Email:** akin2nde@gmail.com

SUNSI Review Complete  
 Template = ADM-013  
 E-RIDS=ADM-03  
 ADD=Sarah Lopas

COMMENT (110)  
 PUBLICATION DATE: 10/29/2018  
 CITATION: 83 FR 54380

## General Comment

There is a growing demand for Targeted Radonuclide Therapies in Sub-Saharan Africa. However there are no regulatory modifications to satisfy the emergence of therapeutic nuclear medicine in Africa. Historically, developing and less developed countries have had to to establish and regulate their practices according to standards set by the West. In reality, developing countries are less able align with global trends.

Fortunately, the intention of the NRC to modify training and experience requirements may favour the emergence of sophisticated therapeutic nuclear medicine in Sub-Saharan Africa. Akin to the early days where the NRC and US researchers assisted the development of nuclear medicine, this comment is to outline a need for feasible development objectives and opportunities for trans boarder cooperation that should ensure the development of therapeutic nuclear medicine, not only in the US but also in other countries of the world.

I hope that a common understanding is reached that ensures a successful implementation/adaptation of therapeutic nuclear medicine in Africa.